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Abstract  
Background. Randall’s plaques, first described by Alexander Randall in the 1930s, are 
small subepithelial calcifications in the renal papillae (RP) that also extend deeply into 
the renal medulla. Despite the strong correlation between the presence of these plaques 
and the formation of renal stones, the precise origin and pathogenesis of Randall’s plaque 
formation remain elusive. The discovery of calcifying nanoparticles (CNP) and their 
detection in many calcifying processes of human tissues has raised hypotheses about their 
possible involvement in renal stone formation.  
Methods. We collected RP and blood samples from 17 human patients who had 
undergone laparoscopic nephrectomy due to neoplasia. Homogenized RP tissues and 
serum samples were cultured for CNP. Scanning electron microscopy (SEM) and energy 
dispersive X-ray spectroscopy (EDS) analysis were performed on fixed RP samples.  
Immunohistochemical staining (IHS) was applied on the tissue samples using CNP-
specific monoclonal antibody (mAb).  
Results. Randall’s plaques were visible on gross inspection in 11 out of 17 collected 
samples. Cultures of all serum samples and 13 tissue homogenates had CNP growth 
within 4 weeks. SEM revealed spherical apatite formations in 14 samples, with calcium 
and phosphate peaks detected by EDS analysis. IHS was positive in 9 out of 17 samples.  
Conclusion. A strong link was found between the presence of Randall’s plaques and the 
detection of CNP, also referred to as nanobacteria. These results suggest new insights 
into the etiology of Randall’s plaque formation, and will help us understand the 
pathogenesis of stone formation. Further studies on this topic may lead us to new 
approaches on early diagnosis and novel medical therapies of kidney stone formation.  
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 Introduction 
Over 65 years ago, Randall performed a detailed examination of the kidney papillae of 
more than 1,000 nonselected cadaveric renal units, and demonstrated that interstitial 
crystals located at, or adjacent to, the papillary tip were common in stone formers [1]. He 
found that these crystals were composed not of calcium oxalate (CaOx), the most 
common solid phase found in patients with nephrolithiasis, but of calcium phosphate 
(CaP) [2], and termed them as plaques. He believed that the CaP crystals precipitated in 
the papillary interstitium and subsequently eroded into the urinary space, serving as a 
nucleation surface for CaOx [2]. In vitro, CaP phases such as apatite efficiently nucleate 
CaOx crystallization [3], so that one can easily conjecture that common CaOx stones 
begin on plaques. Most theories, including that of Randall, have held as axiomatic that 
particle retention must be a prerequisite to stone formation [4]. Finlayson later argued 
that, due to rapid flow of the renal ultrafiltrate through the tubule, there was insufficient 
time for formation of an inralumenal-obstructing solid phase [5], which also suggested 
that an intratubular site of stone formation was unlikely. However, other investigators 
found that CaOx crystals adhered to cultured tubular cells [6], where they could either be 
endocytosed or remain on the cell surface, serving as a nidus for growth into larger, 
clinically significant, calculi.  
In addition to studies of the initiation mechanism of kidney stone formation, other 
nephrolithiasis factors were examined. Between 1980 and 1994 the prevalence of kidney 
stone disease increased by 37% for unknown reasons [7]. In the field of infectious 
diseases, increasing disease rate has been accepted as a possible indicator of infectious 
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agent involvement. For example, a significant increase in stomach ulcer incidence was 
eventually correlated with presence of Helicobacter pylori infection and subsequent 
studies showed that most stomach ulcers are directly caused by this infection [8]. 
Calcifying nanoparticles (CNP), also referred to as nanobacteria, were discovered 
over a decade ago in blood and blood products [9, 10] and correlated with numerous 
pathological-calcification related diseases such as prostatitis [11, 12], arteriosclerosis [13-
16], malignant tumors [17, 18], Alzheimer’s disease [19],  gall stones [20], calciphylaxis 
[21, 22] and polycystic kidney disease [23, 24]. It also has been hypothesized that CNP 
are the initial nidi on which kidney stones develop at a rate dependent on the degree of 
supersaturation of the urine [25-28]. The basic CNP are membrane-enclosed cell-like 
vesicles that are 100 times smaller in volume than common bacteria [10].  These units 
contain no detectable genomic DNA or RNA, but yet appear capable of self propagation 
or replication [29]. We have explored the possibility that such particles could be primitive 
life forms [30]. Although we know their capability of causing specific infection [31], 
general debate continues over the systematic classification of these particles among 
infectious agents. Methods to detect CNP in biological samples, cells, tissues, and blood 
include immuno-detection techniques using anti-CNP mAbs, specific culture techniques 
and electron microscopy [32]. With the help of those developed methodologies, some 
important features of CNP and their triggering effect on nephrolithiasis have been 
suggested by different research teams. These features include:  
1. CNP consist of tiny spheres (50-200nm) resembling cells or liposomes. They 
appear to readily precipitate apatite from their surrounding media forming apatite-
protein complexes. Immuno-electronmicroscopy reveals protein antigens in close 
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proximity to precipitated apatite, suggesting a novel form of protein-associated 
mineralization [33].  
2.  This mineralization starts as extremely small apatite crystals and forms on the 
exterior membrane of 50-200nm diameter CNP followed by a growing shell or an 
enclosing sphere of apatite which may reach a diameter of one to several 
micrometers [34, 35]. 
3. 14% of healthy adults in Scandinavia have anti-CNP antibodies [36]. A high 
fraction (75%) of patient groups with kidney diseases has CNP antigen [37]. 
4. CNP form apatite units/shells in vitro, morphologically and chemically similar to 
those in the core of kidney stones, see Figure 1. [24, 25]. 
5. CNP are renotropic [38].  
6. CNP cause kidney stone formation when injected into rats via percutaneous renal 
puncture [39]. 
7. CNP have been detected in many different types of human kidney stones [25, 28]. 
8. In laboratory experiments, destruction of the calcified apatite shell of CNP with 
EDTA-chelation reveals numerous 50 to 100nm diameter membranous cells [34] 
similar to those observed in Randall plaques by other research groups [4, 40-42]. 
9. Transmission Electron Microscopy (TEM) study of renal plaques shows 1-5 μm 
apatite spheres laminated with mineral and organic molecules [4, 41, 42], similar to 
the structure of CNP shells  [10, 27], see Figure 2.  
Matlaga, et al in their recent review article stated that in the decades since Randall first 
reported his observations there has been little progress in defining the role of plaque in 
the pathogenesis of kidney stone diseases, fundamentally due to lack of appropriate in 
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vivo data [4]. Our goal was to test the hypothesis of CNP-Randall’s plaque association by 
obtaining RP samples from patients whose kidneys have been removed due to neoplasia. 
We present here preliminary evidence that there is a strong association between Randall’s 
plaques and CNP. 
 
Materials and Methods 
 
Subjects  
RP were dissected from 17 patients who had undergone laparoscopic nephrectomy due to 
neoplasia. Presence or absence of Randall’s plaques were noted on gross inspection of 
immediately extracted and bivalved kidneys. Selected papillae were harvested well away 
from the tumor. Tissue samples were prepared for the analyses with SEM, EDS, IHS, and 
CNP culture. Blood was drawn in the fasting state from each patient immediately before 
and after surgery. The serum was extracted and used for CNP culture and enzyme-linked 
immunosorbent assay (ELISA) to detect CNP antigen and antibody. A bladder urine 
sample of each patient was drawn through a urinary catheter and sent for routine urine 
culture. The study was approved by the UCSF Committee on Human Research and every 
patient was given detailed information regarding the procedures involved in this research 
and signed an informed consent prior to any manipulation. 
 
Tissue preparation for analysis  
RP specimens of 17 patients for IHC and SEM experiments were immediately immersed 
in 4% paraformaldehyde and refrigerated overnight. IHS samples were paraffin 
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embedded and prepared for IHS as described earlier [43]. SEM samples were dehydrated 
and gold-coated as described previously [10]. The tissue samples for CNP cultures were 
immediately placed into 2 ml of sterile phosphate buffered saline (PBS), pH 7.4, 
homogenized for 30 seconds, four times, with 30-second cooling intervals on ice using 
conventional, 5-ml glass tissue-grinders. Homogenized tissue was centrifuged at 2500g 
for 15 minutes. The supernatant was separated under sterile conditions and sterile-filtered 
through 0.22μm pore size, non-protein binding filters (Millipore) into sterile non-
adhesive tubes and stored at -70oC until thawed and processed for culture as described 
below.  
 
CNP cultures from serum and tissue samples 
Patient serum samples, and homogenized tissue supernatant samples were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco Lab Inc., Grand Island, NY) 
under mammalian cell culture conditions (37oC, 5-10% CO2, 90-95 % humidity) for four 
weeks. Patient sera were cultured at 10% final concentration, and tissue homogenates 
were cultured both with and without fetal bovine serum (FBS) supplementation which 
was previously tested for CNP and evaluated as CNP negative (Atlanta Biologicals, GA) 
as described earlier [44]. The pellets from the homogenized tissue were incubated with 30 
mM EDTA for 1 hour at room temperature for decalcification, and release of enclosed 
CNP from the apatite units, diluted 1:10 in DMEM, and cultured as described above. 
Each sample was filtered through 0.22 µm filters before culturing in order to eliminate 
potential conventional-bacterial contamination in a Biosafety level-2 facility. Cultures 
were checked for gross bacterial contamination by microscopy and macroscopic 
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observation of turbidity and color change of the medium from the third day of incubation. 
Control culture plates were incubated in parallel with the test plates to determine whether 
spontaneous crystallization can occur in culture medium. The medium was incubated 
with or without FBS. Every week, the culture plates were inspected by phase contrast 
microscopy (Nikon Eclipse TE 2000-U) for CNP growth. Positive identification of CNP 
involved typical slow propagation and optical properties, negative signal with Hoechst 
33258 dye, and positive signal with indirect immunofluorescence staining (IIFS) [10]. All 
culture samples were harvested with 14000g centrifugation for 30 min at 4oC followed by 
30 days of incubation. The pellets were spread on glass slides for IIFS, fixed and double-
stained using CNP surface-antigen-specific mAb 8D10 (Nanobac Oy, Kuopio, Finland), 
followed by Alexa Fluor 488 goat-anti-mouse IgG [32]. In addition, Hoechst stain was 
used to detect conventional bacterial contamination. As a positive control for Hoechst, E. 
coli (nonpathogenic strain HB101) was used. Fluorescence photographs were taken using 
an Olympus BX60F5 microscope coupled to a Nikon digital camera DXM 1200F.  
 
Scanning electron microscopy and energy dispersive X-ray microanalysis  
RP samples 2-4 mm in block size were analyzed both for morphology and chemical 
composition using JEOL 6340 Field Emission SEM with attached IXRF EDS analyzer 
[10]. Each sample was divided into 4 mapping areas and each area was scanned for small, 
100-500 nm spherical forms, and apatite, calcium-rich or phosphate-rich particles. 
Cultured CNP and one oxalate kidney stone (gift from University of Kuopio 
Hospital/Finland) sample were prepared for SEM analysis using the same preparation 
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technique for tissue samples. In EDS analyses, inorganic hydroxyapatite (Sigma, H-0252, 
St. Louis, MO) was used as a reference. 
 
Immunohistochemical analysis of renal papilla samples 
Paraffin embedded RP tissue samples were cut into 5-µm sections, deparaffinized and 
rehydrated [43]. Each tissue section was demineralized in 250 mM sodium citrate for 24 
hours at +4oC, to retrieve apatite crystal-covered epitopes prior to IHS. After washing in 
water, endogenous peroxidase was blocked with 1% H2O2 in methanol for 30 min. Slides 
were then rinsed in PBS before staining with a catalyzed Signal Amplification (CSA) 
IHS (Dako, Carpinteria, CA, USA). Anti-CNP mAb, 8D10, was used as primary antibody 
which is recommended by the manufacturer for detection of CNP in formalin-fixed 
paraffin embedded tissue sections. All slides were counterstained with hematoxylin, and 
mounted with glycerol. Negative control sections went through the same staining process, 
except that the primary mAb step was omitted.  
  
Biochemical Assays 
All blood specimens were obtained in the early morning and after an overnight fast, 
before and after surgery. Serum samples were prepared within 2 hours and kept frozen at 
-70oC until analyzed. The commercially available ELISA kits for detecting anti-CNP IgG 
and CNP antigen; Nano-Sero IgG, and Nanocapture (Nanobac Oy, Finland) respectively 
were used. All measurements were run in duplicates. 
Nano-Sero IgG ELISA measures quantitatively a cumulative immune reaction to the 
antigen complex in special conformation on CNP, and includes for instance heterophilic 
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antibodies and auto-antibodies. Nanocapture ELISA measures quantitatively CNP from a 
50μl serum sample. The detection antibody recognizes CaP-binding protein-antigen on 
CNP in a special CaP complex conformation (ELISA kit inserts).  
 
Statistical analysis  
Tissue samples for 17 patients were analyzed with several techniques and measurements 
in the form of a rating recorded. The serum and tissue homogenate cultures for CNP had 
a rating of (4)= growth in one week, (3)= growth in two weeks, (2)= growth in three 
weeks, (1)= growth in four weeks, (0)= no growth in four weeks of incubation. SEM was 
rated as (0) if no CNP was observed, (1) if CNP were seen in one of the four mapped 
areas, (2) if CNP were seen two of the four mapped area, (3) if CNP were seen three of 
the four mapped area, and (4) if CNP were seen in every scanned area at 1500X 
magnification. The Nanocapture and Nano-sero ELISA performed on 16 patient sera, and 
values obtained for CNP antigen and antibody tests were evaluated as follows: for 
Nanocapture ELISA: (0) indicates < 3.5 units/ml; (1) > 3.5-11.0 units/ml; (2) > 11.0-50.0 
units/ml; (3) > 50.0-150 units/ml; (4) > 150 units/ml. For Nano-sero ELISA: (0) indicated 
< 0.1 units/ml; (1) > 0.1 - 0.4 units/ml; (2) > 0.4 - 0.5 units/ml; (3) > 0.5 - 0.7 units/ml; 
(4) > 0.7 units/ml. 
While no control subjects were observed in this study, historical data from our other 
CNP-related experiments on healthy subjects is available [36] and discussed further in the 
Discussion. Summary tables were used to describe the ratings taken and a logistic 
regression model with a random effect for subject was used to test for agreement between 
the tissue-tests performed when ratings are categorized as a positive or negative result. 
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Results 
 
Subjects 
Eleven male and 6 female patients were enrolled in our study, with a mean age of 65.5 
and 78 years, respectively. Randall’s plaques were observed on the RP of 11 patients 
(Table 1), with no sexual preponderance. No correlation was found between the 
observation of Randall’s plaques and the patients’ tumor types or their past medical 
histories. Urine cultures were negative in 12 patients, showed mild growth of genital flora 
in 3 patients and were positive for enterococcus species in 2 patients. 
 
CNP cultures of serum samples and tissue homogenates 
All serum samples and 13 of 17 RP tissue homogenates and tissue pellets grew CNP at 
different growth rates (Tables 1 and 2). Some samples were already positive within three 
days of culture. All growth-positive samples stained positive with IIFS using anti-CNP 
mAb, 8D10 (Fig. 3A), but stained negative with the Hoechst (Fig. 3B), indicating no 
bacterial contamination in cultures. The positive control for Hoechst dye, E. coli, was 
stained blue (Fig. 3C), but no signal was detected with 8D10 (Fig. 3D). Electron 
microscopic observation of cultured CNP showed typical morphology of CNP (Fig 4A), 
but no protein precipitation or inorganic type crystal formation was observed as we have 
described the comparisons of those particular morphologies earlier [26, 29]. In negative 
controls, no CNP growth, no mineralization or protein precipitation was observed during 
the one-month follow-up.  
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Scanning Electron Microscopic Analysis 
Fourteen of 17 tissue samples contained CNP shell-like particles in variable sizes (Fig. 4 
B-D and Fig 5B) which also produced CaP peaks under EDS analysis identical to that of 
CNP (Fig 5C). The tissue samples without visible, macroscopic plaques had fewer or no 
spherical apatite formations compared with samples with visible plaques (Figure 6).  The 
tissue cells with those apatite particles looked more deformed with fibrous formation 
(Figs. 4 C, D and 6F) whereas the negative tissue cells looked more intact with a healthy 
tissue appearance (Figs. 5A and 6G). The apatite spheres produced an EDS pattern (Fig. 
5C) identical to the CNP EDS patterns as observed in our earlier studies [10, 25, 26]. 
 
Immunohistochemistry 
The results of RP samples analyzed using IHS is summarized in Table 1. Nine out of 17 
tissue samples stained positive for CNP antigen. Positive staining results as a brown-
colored precipitate at the antigen site is shown in Fig.7 A, B and F. Negative controls that 
were stained with the same technique by omitting the mAb, did not show any non-
specific brown staining (Fig 7 E).  
 
ELISA 
Out of 16 tested serum samples, 14 were positive for CNP-antigen, and 11 were positive 
for CNP-antibody. Nano-Sero IgG, and Nanocapture ELISA test results are summarized 
at Tables 1 and 2. 
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Statistical Results 
Ratings in the experiment results were categorized into positive and negative groups, and 
results of a logistic regression model with a random effect for subject yield a p-value of 
p=0.2427 for the statistical test of an overall difference between tissue sample tests. The 
results for the serum culture for CNP were excluded from this statistical test since all 
subjects recorded a positive rating. Thus there is a lack of evidence for rejecting the null 
hypothesis of a difference between the results of the seven tissue sample tests and we can 
conclude that the tissue sample test results did not differ for the different techniques used. 
 
Discussion 
Plaques, defined as sites of interstitial crystal deposition at or near the papilla tip, are 
found in kidneys of CaOx-stone formers (100%) and often, but less frequently, in people 
who do not form CaOx stones (43%) [45]. Stoller and colleagues used high-resolution 
radiography to examine 50 consecutive sets of cadaveric kidneys [46]. Renal medullary 
calcification that extended deep into papillae was identified in 57%. When histologically 
examined, the calcification was localized to the basement membrane of collecting tubules 
and vesa recta, as well as within the papillary interstitium. One major question is to 
determine how plaques themselves form, on what structures, and in response to what 
driving forces? Until the studies by Evan et al. [47, 48], we did not have an answer to 
these rather elementary questions. These investigators performed kidney biopsies on 
stone-forming patients to determine the anatomical site and composition of the initial 
solid phase. In calcium oxalate stone formers, they found initial CaP (apatite) 
crystallization in the basement membrane of the thin limbs of the loop of Henle with 
 13
Neva Ciftcioglu 06/11 /07                                            renal papilla and calcifying nanoparticles 
Final 
subsequent extension to the vasa recta, then to the interstitial tissue surrounding the 
terminal collecting ducts, and finally, in the most severe cases, to the papillae. Contact of 
these crystals with urine, supersaturated with respect to calcium oxalate, may have 
promoted heterogeneous nucleation and formation of kidney stones. Non-stone formers, 
subjected to nephrectomy had neither plaque nor crystals [47-49].  
Now that we know where the initial solid phase forms, and the potential metabolic 
factors provoking the stone formation, what are the next questions? The common 
paradigm is that the cores of kidney stones are made of apatite. Randall described 
papillary calculi as formations characteristically having a smooth convex surface and a 
concave surface, which he believed to be the site of papillary implantation [1, 2]. Why 
there was a common morphology in these formations if they were simple crystal 
depositions, and the reason of apatite crystal accumulation in the first place always 
remained elusive.  
The discovery of CNP encapsulated in a CaP shell, and their subsequent detection in 
several human pathologic calcification processes, raised hopes for an explanation for 
Randall’s plaques [34]. Soon after their discovery, the CNP were detected in urinary 
stones recovered from human patients [25, 28]. Inspired by these observations, we 
hypothesized that CNP might actually be the initiating agents in the formation of 
Randall’s plaques and subsequently the renal stones. 
Matlaga et al have used high power imaging, micro fourier transformed 
microspectroscopy, electron diffraction analysis on Randall’s plaques and concluded that 
they are formed of spherical, biological apatite particles [4]. Those are very similar in 
morphology and composition to cultured shells of CNP (Figs 1B, 4A) [10, 25-27]. In our 
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earlier TEM analysis of CNP shells we defined their morphology as “tree-age-ring-like” 
formations of crystal and organic matter [27], a description which is almost identical to 
Coe et al’s [41], and Matlaga et al’s [4] observations in Randall’s plaques (Fig. 2). We 
also have observed apatite spherical formations in the core of every kidney stone 
independent of their overall chemical composition of the kidney stones (Fig. 1) and 
cultured CNP from those stones [25]. Other independent studies also support our 
hypothesis that CNP may instigate kidney stone nucleation and growth [28, 34, 50-53].   
The other research strengthening our hypothesis shows that bone-associated proteins, 
including osteopontin (OPN), bone morphogenetic protein 2 (BMP-2), alkaline 
phosphatase, matrix Gla protein, osteocalcin, bone sialoprotein, urinary prothrombin 
fragment 1 and type 1 collagen, have a role in plaque formation [54-58]. Kumar et al 
hypothesized that renal cells in culture can assume an osteoblast-like phenotype, express 
the matrix proteins OPN and BMP, and form calcified nodules [34]. These studies 
provide support for the hypothesis that renal cells may promote the formation of 
Randall’s plaques, perhaps via expression of matrix proteins. Kajander et al described 
similar calcification promoting proteins on the surface of CNP (unpublished data).  
CNP have unique properties including extremely small “cell” size (0.1-0.5 µm), and 
rapid in situ precipitation of CaP from blood and other body fluids under conditions not 
normally conducive to such precipitation [10]. The “cells” and associated apatite surfaces 
may act like a magnet to bind those kinds of proteins from the blood circulation, and 
enhancing calcification in the cells where they are attached and/or internalized. CNP are 
renotropic, as reported from rabbit experiments using radiolabelled CNP and are 
eliminated from the circulation through urinary excretion [38]. In another study, it was 
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shown that translumbar, percutaneous intrarenal injection of CNP into rats resulted in 
kidney stone formation [39]. In our earlier experiments, we have infected rats with IV 
CNP and observed strongly positive IHS results with specific CNP mAb especially 
localized at kidney glomerulus [24]. In this research, we appreciate similar findings with 
the renal plaque positive patients samples (Fig. 7A, B). Whether CNP themselves serve 
as the nucleus for crystal formation, or they are simply able to lower the activation energy 
barrier and thus allow precipitation and growth of crystals under much lower 
supersaturation conditions is yet to be determined. For evaluating the results of this study, 
it is immaterial whether or not CNP are even actual life forms or located into a certain 
category in Bergey’s Manual, or some kind of vesicles or liposomes; their properties of 
promoting rapid crystallization and growth of calcium rich minerals are well established, 
and their involvement in other pathological calcification related diseases have been 
studied [24-27, 29]. 
Nephrolithiasis is a significant urological disease afflicting a large percentage of US 
population costing approximately 2.39 billion dollars per year [4]. Initial diagnosis of a 
kidney stone is frequently acute in onset, and commonly requires a variety of 
interventions. To reduce the likelihood of recurrence, it is necessary to understand the 
mechanisms involved in stone formation and to determine urinary markers of stone 
initiation. Earlier it was thought that knowing the site of initial crystallization would 
improve our understanding of the pathogenesis of stone formation and allow investigators 
to propose more focused hypotheses. This would help devise effective therapies aimed at 
preventing recurrent nephrolithiasis, which afflicts approximately 50% of stone formers 
within five years of the initial stone [59]. However, if there is an unknown causative 
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agent, the treatment approach will remain non-specific, palliative, and eventually 
ineffective, while the root cause remains unsolved. To a great extent, our studies accord 
with and confirm much of Randall’s pioneering work. Plaque is interstitial and composed 
of apatite. What we add, here, is that the apatite formations are culturable, stainable with 
CNP-specific monoclonal antibodies, and the formation of nuclei or nidi apatite 
precipitates seems to be controlled by CNP.  This important finding needs to be 
confirmed with a research design including a larger patient population and negative 
controls. We have developed diagnostic tools for this unique agent, and also found that 
CNP are susceptible to certain antibiotics [60].  If supported by further work, this 
hypothesis may lead to treatment designed to disable the CNP, prevent or control the 
precipitation of apatite, and treat the formation of kidney stones as a consequence of an 
infection. 
 
Conclusion 
We found a strong association between Randall’s plaque of human kidneys, and the 
presence of CNP. While the results reported in this preliminary research are limited with 
only 17 patient samples and there are no plaque-negative renal samples involved, the 
presented hypothesis is critical and opens further discussions in the urology arena. 
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Table 1. Overall Results for Tissue Sample Tests. 
 
Result  
Observed 
Presence 
of 
Randall’s 
plaques 
Serum 
culture 
for 
CNP  
Tissue 
homogenate 
culture for 
CNP 
SEM EDS IH ELISA Ag* 
ELISA 
Ab* 
Negative 6 0 4 3 3 8 2 5 
Positive 11 17 13 14 14 9 14 11 
* Missing response for Subject 17 
 
Table 2: Ratings for CNP, SEM, and ELISA Tissue Sample Tests. 
 
Rating Serum 
culture 
for 
CNP 
Tissue 
homogenate 
culture for 
CNP 
SEM ELISA Ag* 
ELISA 
Ab* 
0 0 4 3 2 5 
1 7 7 3 3 10 
2 2 5 2 5 1 
3 5 1 7 2 1 
4 3 0 2 4 0 
* Missing response for Subject 17 
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Figures 
 
A B
 
Figure 1. SEM images of apatite spheres in various sizes in the core of an oxalate kidney 
stone (A), apatite formations in the CNP culture (B). Bars= A; 1μm, B; 10μm. 
 
 
Neva Ciftcioglu 06/11 /07                                            renal papilla and calcifying nanoparticles 
Final 
 
 
 
Detected 
spheres in 
Randall’s 
plaques 
Calcifying  
Nanoparticles 
A B
C D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Morphological similarities of published TEM images of spherical, apatite 
containing formations in renal papilla (A and B), and CNP (C and D). Magnifications: A, 
20,000X; B 30,000X; C and D, bars 200nm.  
 
Reprinted from; A:  Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 
115:2598-2608, 2005 [41] with permission from American Urological Association. B: 
Matlaga BR, Coe FL, Evan AP, Lingeman JE. The role of Randall's plaques in the 
pathogenesis of calcium stones. J Urol. 177:31-38, 2007 [4] with permission from 
American Urological Association. C: Kajander EO, Ciftcioglu N. Nanobacteria: an 
alternative mechanism for pathogenic intra- and extracellular calcification and stone 
formation. Proc Natl Acad Sci U S A. 95:8274-8279, 1998 [10] with permission from 
copyright 1998 National Academy of Sciences USA. D: Kajander EO, Ciftcioglu N, Aho 
K, Garcia-Cuerpo E. Characteristics of nanobacteria and their possible role in stone 
formation. Urol Res. 31:47-54, 2003 [27] with kind permission from Springer Science 
and Business Media. 
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igure 3. Light microscopic images of double staining results of patient samples cultured 
nder CNP culture conditions. (A) IIFS positive cultured patient sample recognizing the 
NP specific monoclonal antibody when imaged with the green bandpass emission filter, 
 Negative results of Hoechst die the same sample (A) imaged with the blue bandpass 
mission filter. (C) IIFS negative bacterial control (nonpathogenic E. coli strain HB101) 
ot recognizing the CNP specific monoclonal antibody with green bandpass emission 
 (D) Positive results of Hoechst die the same sample (C) imaged with the blue 
andpass emission filter. 
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C D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. SEM images of (A): cultured CNP from a serum sample, (B, C, and D) CaP 
spheres detected on renal papilla (Randall’s plaque). Bars; 2μm. 
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Figure 5. SEM analysis of renal papilla. A, Renall cells with no plaques. B, renal cells 
with plaque formations showing bumpy surface. White arrows show the spherical apatite 
formations on cells. C, EDS analysis of the one representative apatite sphere on the cells 
shown in B. 
Neva Ciftcioglu 06/11 /07                                            renal papilla and calcifying nanoparticles 
Final 
 32
B C E
Relatively large calcified plaques. (C) A cross section through the renal 
papilla, showing sub-epithelial calcifications running deep into the renal medulla. A 
closer images of renal papilla tissue with (D) and without eye-visible plaque formations 
(E). (F) and G are SEM images of the tissues shown at (D) and (E) respectively. Black 
arrows show streaks of plaques on the tissue, white small arrows show the apatite spheres 
on the tissue. Bars: F and G are 10μm.  
 
 
 
 
 
 
Figure 6. Images from Randall’s plaques. (A) Tiny calcifications at the tip of the renal
papilla. (B) 
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Figure 7. Immunohistochemical  (IHS) staining of paraffin embedded renal papilla tissue 
by using anti-CNP monoclonal antibody. Brown color shown by black arrows indicates 
positive signal (existence of CNP antigen) in the tissue. The images shown at A (100X) 
nd B (400X) are from IHS-positive tissue. C (100X) and D (400X) are from IHS-
egative tissue, E and F (200X) are consecutive sections from a positive tissue. E is 
ained by omitting the monoclonal antibody, showing no positive signal whereas in F 
ositively stained in one of the collecting ducts. 
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